Hosted on MSN
Oral Drug Wins FDA Approval for Chronic Hives
The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday. Indicated for adults with stubborn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results